Perrigo Rogaine foam ANDA draws suit
This article was originally published in The Tan Sheet
Executive Summary
The Allegan, Mich., private labeler reports Oct. 13 it is the first to file an abbreviated new drug application for minoxidil topical aerosol foam, 5 percent, equivalent to Johnson & Johnson's hair re-growth OTC Men's Rogaine Foam. Patent holder and GlaxoSmithKline subsidiary Stiefel filed an infringement suit Oct. 9 against the private-label firm, initiating a 30-month stay against generic competition under the Hatch-Waxman Act. Perrigo said the branded version generates about $52 million in annual sales. Patents for Rogaine Foam, launched in 2006 by Pfizer, run through 2019. While Stiefel owns the Rogaine Foam patent, J&J holds the NDA (1"The Tan Sheet" Sept. 11, 2006)
You may also be interested in...
Rogaine Foam Patents To Keep Product Covered Through 2019, Pfizer Says
Pfizer Consumer Healthcare's new foam delivery form ofRogaine (minoxidil) carries three years of marketing exclusivity and is patent-protected through 2019, the firm announced Sept. 5
MoCRA Registrants Encouraged By Glimpse Into Cosmetics Direct Portal, But Apprehensions Remain
Jessica O’Connell, partner at Covington & Burling, is getting questions from clients about the electronic system the FDA plans to launch in coming weeks for cosmetics manufacturers to register facilities and list products as required by new cosmetics regulations. It remains to be seen how hard the 29 December 2023 deadline will be for companies to get their information submitted.
Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope
Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.